Table 1.
Baseline Characteristics of Patients
| Lenvatinib Group (n=27) | Lenvatinib Plus Camrelizumab Group (n=21) | P | |
|---|---|---|---|
| Age,years | |||
| >45 | 19 | 17 | 0.401 |
| ≤45 | 8 | 4 | |
| Gender | |||
| Male | 24 | 19 | 0.858 |
| Female | 3 | 2 | |
| ECOG-PS | |||
| 0 | 18 | 17 | 0.269 |
| 1 | 9 | 4 | |
| AFP (ng/mL) | |||
| <400 | 11 | 12 | 0.259 |
| ≥400 | 16 | 9 | |
| HBsAg | |||
| - | 2 | 4 | 0.226 |
| + | 25 | 17 | |
| TBil (mean±SD (umol/L)) | 19.90 (16.39–23.88) | 15.47 (12.35–18.42) | 0.363 |
| ALB (mean±SD (g/L)) | 39.37 (37.91–41.26) | 39.90 (37.58–42.07) | 0.328 |
| PT (mean±SD (s)) | 13.52 (13.04–14.01) | 13.02 (12.3–13.83) | 0.522 |
| Child-pugh score | |||
| 5~6 | 25 | 19 | 0.792 |
| 7 | 2 | 2 | |
| Cirrhosis | |||
| No | 3 | 2 | 0.858 |
| Yes | 24 | 19 | |
| Tumor type | |||
| Primary | 11 | 8 | |
| Relapse | 16 | 13 | 0.853 |
| Portal vein thrombus | |||
| No | 15 | 10 | 0.225 |
| I/II | 1 | 4 | |
| III/IV | 11 | 7 | |
| Extrahepatic metastasis | |||
| No | 10 | 11 | 0.288 |
| Yes | 17 | 10 | |
| Previous treatment | |||
| First-line | 6 | 3 | 0.547 |
| Second-lines | 10 | 11 | |
| Third-lines or more | 11 | 7 |
Abbreviations: ECOG-PS, Eastern Cooperative Oncology Group Performance Status; AFP, α‐fetoprotein; ALB, albumin, PT, prothrombin time.